Insulin injections once-a-week on the horizon for people with type 2 diabetes 27 July 2021 For millions of people living with type 2 diabetes the burden of daily injections is a challenge, but new results from clinical trials suggest a once-a-week shot may be as safe and effective. The game-changing study published in Diabetes Care, investigated the drug icodec, an insulin with a half-life of 196 hours over eight days. The drug works by modifying the insulin molecule to keep it from being broken down by enzymes and maintains a steady insulin release by binding to proteins produced in the liver. The research from UT Southwestern suggests the once-weekly treatment could break barriers for people who struggle with the fear and inconvenience of daily injections. “This treatment will also decrease the burden on those who care for patients with diabetes requiring insulin. For example, for patients who need help injecting, those living in long-term care facilities and those with memory problems, a once-weekly insulin will facilitate treatment and decrease the burden on care providers.” Maintaining regular insulin treatment is an ongoing challenge for millions of people with type 2 diabetes around the world. In the phase 2 clinical trials, 205 patients from seven countries including the US and Europe participated to test the efficacy and safety of the drug over 23 weeks. The participants were divided into four groups – a control group that continued receiving daily injections of insulin and three experimental groups that received weekly icodec shots. These three groups were used to calculate the dose required to stabilise a patient’s blood glucose level. In all three groups, the new drug worked well with no episodes of severe hypoglycemia recorded. The study found that starting with a higher dose at first helped patients reach their optimal glucose target quicker. A large phase 3 clinical trial is already underway, which will evaluate the efficacy of weekly icodec doses in patients with either type 1 or 2 diabetes. For more information on the types of insulin and how it is administered you can go to here.
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Good Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
Blog 22 July 2026 Living Out Loud: how Australia spoke up for National Diabetes Week 2026 From 12 to 18 July, Australians living with diabetes, alongside their carers, researchers, health professionals and clinicians, did something powerful. They... Continue Reading
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading
